may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).tapentadoltapentadol and loxapine inhaled both increase sedation. Use Caution/Monitor.temazepamtemazepam and loxapine inhaled both increase sedation. Use Caution/Monitor.terbutalineloxapine inhaled increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.tetrabenazineloxapine inhaled and tetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.thioridazineloxapine inhaled and thioridazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.loxapine inhaled and thioridazine both increase sedation. Use Caution/Monitor.thiothixeneloxapine inhaled and thiothixene both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.loxapine inhaled and thiothixene both increase sedation. Use Caution/Monitor.tiotropiumloxapine inhaled increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.tiotropium decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.tolterodineloxapine inhaled increases effects of tolterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.tolterodine decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.topiramateloxapine inhaled and topiramate both increase sedation. Modify Therapy/Monitor Closely.tramadoltramadol and loxapine inhaled both increase sedation. Use Caution/Monitor.tranylcyprominetranylcypromine, loxapine inhaled. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).trazodoneloxapine inhaled and trazodone both increase sedation. Use Caution/Monitor.triazolamtriazolam and loxapine inhaled both increase sedation. Use Caution/Monitor.triclofostriclofos and loxapine inhaled both increase sedation. Use Caution/Monitor.trifluoperazineloxapine inhaled and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.loxapine inhaled and trifluoperazine both increase sedation. Use Caution/Monitor.trihexyphenidylloxapine inhaled increases effects of trihexyphenidyl by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.trihexyphenidyl decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.trimipramineloxapine inhaled and trimipramine both increase sedation. Use Caution/Monitor.triprolidinetriprolidine and loxapine inhaled both increase sedation. Use Caution/Monitor.trospium chlorideloxapine inhaled increases effects of trospium chloride by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.trospium chloride decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.vecuroniumloxapine inhaled increases effects of vecuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.vecuronium decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.venlafaxinevenlafaxine, loxapine inhaled. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).vilazodonevilazodone, loxapine inhaled. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).xylometazolineloxapine inhaled increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.yohimbineloxapine inhaled increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ziconotideloxapine inhaled and ziconotide both increase sedation. Use Caution/Monitor.ziprasidoneloxapine inhaled and ziprasidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.loxapine inhaled and ziprasidone both increase sedation. Use Caution/Monitor.zolmitriptanzolmitriptan, loxapine inhaled. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).zotepineloxapine inhaled and zotepine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.loxapine inhaled and zotepine both increase sedation. Use Caution/Monitor.Minor (6)brimonidinebrimonidine increases effects of loxapine inhaled by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.chasteberrychasteberry decreases effects of loxapine inhaled by pharmacodynamic antagonism. Minor/Significance Unknown. (Theoretical interaction).ethanolethanol, loxapine inhaled. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.eucalyptusloxapine inhaled and eucalyptus both increase sedation. Minor/Significance Unknown.sageloxapine inhaled and sage both increase sedation. Minor/Significance Unknown.smokingsmoking decreases levels of loxapine inhaled by affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown.abobotulinumtoxinAMonitor Closely (1)abobotulinumtoxinA increases effects of loxapine inhaled by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.aclidiniumMonitor Closely (2)loxapine inhaled increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. aclidinium decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.albuterolMonitor Closely (1)loxapine inhaled increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.alfentanilMonitor Closely (1)alfentanil and loxapine inhaled both increase sedation. Use Caution/Monitor.almotriptanMonitor Closely (1)almotriptan, loxapine inhaled. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).alprazolamMonitor Closely (1)alprazolam and loxapine inhaled both increase sedation. Use Caution/Monitor.amisulprideContraindicated (1)amisulpride, loxapine inhaled. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.amitriptylineMonitor Closely (1)loxapine inhaled and amitriptyline both increase sedation. Use Caution/Monitor.amobarbitalMonitor Closely (1)amobarbital and loxapine inhaled both increase sedation. Use Caution/Monitor.amoxapineMonitor Closely (2)loxapine inhaled and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely. loxapine inhaled and amoxapine both increase sedation. Use Caution/Monitor.anticholinergic/sedative combosMonitor Closely (2)loxapine inhaled increases effects of anticholinergic/sedative combos by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. anticholinergic/sedative combos decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.apomorphineMonitor Closely (1)loxapine inhaled and apomorphine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)loxapine inhaled decreases effects of apomorphine by pharmacodynamic antagonism. Contraindicated.arformoterolMonitor Closely (1)loxapine inhaled increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.aripiprazoleMonitor Closely (2)aripiprazole and loxapine inhaled both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. aripiprazole and loxapine inhaled both increase sedation. Use Caution/Monitor.armodafinilMonitor Closely (1)loxapine inhaled increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.atracuriumMonitor Closely (2)loxapine inhaled increases effects of atracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. atracurium decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.atropineMonitor Closely (2)loxapine inhaled increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. atropine decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.atropine IV/IMMonitor Closely (2)loxapine inhaled increases effects of atropine IV/IM by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. atropine IV/IM decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.azelastineMonitor Closely (1)azelastine and loxapine inhaled both increase sedation. Use Caution/Monitor.baclofenMonitor Closely (1)baclofen and loxapine inhaled both increase sedation. Use Caution/Monitor.belladonna alkaloidsMonitor Closely (2)loxapine inhaled increases effects of belladonna alkaloids by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. belladonna alkaloids decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.belladonna and opiumMonitor Closely (3)loxapine inhaled increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. belladonna and opium decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor. belladonna and opium and loxapine inhaled both increase sedation. Use Caution/Monitor.benperidolMonitor Closely (2)benperidol and loxapine inhaled both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. benperidol and loxapine inhaled both increase sedation. Use Caution/Monitor.benzhydrocodone/acetaminophenSerious - Use Alternative (1)benzhydrocodone/acetaminophen, loxapine inhaled. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.benzphetamineMonitor Closely (1)loxapine inhaled increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.benztropineMonitor Closely (2)loxapine inhaled increases effects of benztropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. benztropine decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.brexanoloneMonitor Closely (1)brexanolone, loxapine inhaled. Either increases toxicity of the other by sedation. Use Caution/Monitor.brimonidineMinor (1)brimonidine increases effects of loxapine inhaled by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.bromocriptineSerious - Use Alternative (1)loxapine inhaled decreases effects of bromocriptine by pharmacodynamic antagonism. Contraindicated.brompheniramineMonitor Closely (1)brompheniramine and loxapine inhaled both increase sedation. Use Caution/Monitor.buprenorphineMonitor Closely (1)buprenorphine and loxapine inhaled both increase sedation. Use Caution/Monitor.buprenorphine buccalMonitor Closely (1)buprenorphine buccal and loxapine inhaled both increase sedation. Use Caution/Monitor.buprenorphine, long-acting injectionMonitor Closely (1)loxapine inhaled increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.butabarbitalMonitor Closely (1)butabarbital and loxapine inhaled both increase sedation. Use Caution/Monitor.butalbitalMonitor Closely (1)butalbital and loxapine inhaled both increase sedation. Use Caution/Monitor.butorphanolMonitor Closely (1)butorphanol and loxapine inhaled both increase sedation. Use Caution/Monitor.cabergolineSerious - Use Alternative (1)loxapine inhaled decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated.caffeineMonitor Closely (1)loxapine inhaled increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.calcium/magnesium/potassium/sodium oxybatesSerious - Use Alternative (1)loxapine inhaled, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.carbinoxamineMonitor Closely (1)carbinoxamine and loxapine inhaled both increase sedation. Use Caution/Monitor.carisoprodolMonitor Closely (1)carisoprodol and loxapine inhaled both increase sedation. Use Caution/Monitor.chasteberryMinor (1)chasteberry decreases effects of loxapine inhaled by pharmacodynamic antagonism. Minor/Significance Unknown. (Theoretical interaction).chloral hydrateMonitor Closely (1)chloral hydrate and loxapine inhaled both increase sedation. Use Caution/Monitor.chlordiazepoxideMonitor Closely (1)chlordiazepoxide and loxapine inhaled both increase sedation. Use Caution/Monitor.chlorpheniramineMonitor Closely (1)chlorpheniramine and loxapine inhaled both increase sedation. Use Caution/Monitor.chlorpromazineMonitor Closely (2)chlorpromazine and loxapine inhaled both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. chlorpromazine and loxapine inhaled both increase sedation. Use Caution/Monitor.chlorzoxazoneMonitor Closely (1)chlorzoxazone and loxapine inhaled both increase sedation. Use Caution/Monitor.cinnarizineMonitor Closely (1)cinnarizine and loxapine inhaled both increase sedation. Use Caution/Monitor.cisatracuriumMonitor Closely (2)loxapine inhaled increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. cisatracurium decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.clemastineMonitor Closely (1)clemastine and loxapine inhaled both increase sedation. Use Caution/Monitor.clomipramineMonitor Closely (1)loxapine inhaled and clomipramine both increase sedation. Use Caution/Monitor.clonazepamMonitor Closely (1)clonazepam and loxapine inhaled both increase sedation. Use Caution/Monitor.clonidineMonitor Closely (1)clonidine, loxapine inhaled. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.clorazepateMonitor Closely (1)clorazepate and loxapine inhaled both increase sedation. Use Caution/Monitor.clozapineMonitor Closely (2)clozapine and loxapine inhaled both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. clozapine and loxapine inhaled both increase sedation. Use Caution/Monitor.codeineMonitor Closely (1)codeine and loxapine inhaled both increase sedation. Use Caution/Monitor.cyclizineMonitor Closely (3)loxapine inhaled increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. cyclizine decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor. cyclizine and loxapine inhaled both increase sedation. Use Caution/Monitor.cyclobenzaprineMonitor Closely (3)loxapine inhaled increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. cyclobenzaprine decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor. cyclobenzaprine and loxapine inhaled both increase sedation. Use Caution/Monitor.cyproheptadineMonitor Closely (1)cyproheptadine and loxapine inhaled both increase sedation. Use Caution/Monitor.dantroleneMonitor Closely (1)dantrolene and loxapine inhaled both increase sedation. Use Caution/Monitor.daridorexantMonitor Closely (1)loxapine inhaled and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression,